Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,293 papers from all fields of science
Search
Sign In
Create Free Account
capmatinib
Known as:
2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide
An orally bioavailable inhibitor of the proto-oncogene c-Met (also known as hepatocyte growth factor receptor (HGFR)) with potential antineoplastic…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Narrower (1)
INC280
Broader (2)
Imidazoles
Triazines
NCIt Antineoplastic Agent Terminology
Receptor Tyrosine Kinase Inhibition
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor
Takahito Hara
,
Akiko Kimura
,
+4 authors
J. Soeda
Biochemistry and Biophysics Reports
2020
Corpus ID: 211098160
2020
2020
Tepotinib efficacy in an NSCLC patient with brain metastasis harboring an HLA-DRB1-MET gene fusion.
F. Blanc-Durand
,
Raafat Alameddine
,
+9 authors
M. Florescu
The Oncologist
2020
Corpus ID: 220796882
Alterations in c-MET, a tyrosine kinase receptor encoded by the MET gene, have been reported in in approximately 3% of NSCLC and…
Expand
2019
2019
OA01.07 Capmatinib (INC280) in METΔEX14-Mutated Advanced NSCLC: Efficacy Data from the Phase 2 Geometry MONO-1 Study
R. Heist
,
J. Wolf
,
+15 authors
E. Garon
Journal of Thoracic Oncology
2019
Corpus ID: 208381548
2019
2019
Going After METex14 in NSCLC.
Cancer Discovery
2019
Corpus ID: 190536356
Patients with non-small cell lung cancer harboring MET exon 14 skipping mutations have commonly been treated with the multikinase…
Expand
2019
2019
Syndromes de relargage cytokinique chez des patients traités pour un mélanome métastatique
G. Guichard
,
N. Malissen
,
+4 authors
J. Grob
2019
Corpus ID: 214175824
2018
2018
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
B. Ku
,
Moon Ki Choi
,
+4 authors
M. Ahn
PLoS ONE
2018
Corpus ID: 4789007
AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after…
Expand
2018
2018
Capmatinib and gefitinib combination therapy: will EGFR-mutated MET-dysregulated NSCLC "capitulate"?
B. Ko
,
B. Halmos
Translational Lung Cancer Research
2018
Corpus ID: 59352521
The mesenchymal-epithelial transition factor (MET)/hepatocyte growth factor (HGF) axis is a key pathway in acquired resistance…
Expand
2018
2018
Preliminary activity of capmatinib with gefitinib in NSCLC.
T. Burki
The Lancet Oncology
2018
Corpus ID: 52176200
2017
2017
ACTR-74. A PHASE IB/II, OPEN-LABEL, MULTICENTER STUDY OF CAPMATINIB (INC280) ALONE AND IN COMBINATION WITH BUPARLISIB (BKM120) IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA
M. Bent
,
A. Azaro
,
+13 authors
W. Wick
2017
Corpus ID: 80227598
BACKGROUND c-MET and PI3K pathways are dysregulated in GBM and can drive cancer growth in pre-clinical models. INC280 is a small…
Expand
2016
2016
A phase (Ph) II study of the efficacy and safety of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced hepatocellular carcinoma (HCC).
T. Tanwandee
,
W. Sukeepaisarnjaroen
,
+13 authors
S. Qin
2016
Corpus ID: 78859484
4074Background: Overexpression/activation of cMET occurs in 20‒48% of HCC, and predicts worse survival. Capmatinib (INC280) is a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE